Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease

BACKGROUND: Respiratory syncytial virus (RSV) is a viral pathogen that causes annual epidemics of lower respiratory tract infection with substantial morbidity and mortality in young children, especially those with congenital heart disease (CHD). Palivizumab is the only immunoprophylaxis therapy appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammed, Mohammed Hassan A., Agouba, Rihab, Obaidy, Islam El, Alhabshan, Fahad, Abu-Sulaiman, Riyadh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868616/
https://www.ncbi.nlm.nih.gov/pubmed/33550912
http://dx.doi.org/10.5144/0256-4947.2021.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868616/
https://www.ncbi.nlm.nih.gov/pubmed/33550912
http://dx.doi.org/10.5144/0256-4947.2021.31

Ejemplares similares